Does allopurinol regress left ventricular hypertrophy in patients with treated essential hypertension?

The University of Dundee and NHS Tayside (UK)0 个研究点目标入组 72 人开始时间: 2014年10月3日最近更新: 2019年8月26日

适应症

试验速览

•1. Aged over 18 years
•2. Previously diagnosed with essential hypertension
•3. Been on stable antihypertensive therapy for at least 3 months prior to study screening
•4. Have screening ABPM (or home based BP monitoring if ABPM not tolerated) with daytime average systolic <135mmHg or 24-hour average systolic = 130mmHg
•5. Have screening echocardiography based diagnosis of LVH based on ASE criteria (males >115g/m2, females >95g/m2)

•1. Documented intolerance to allopurinol
•2. Left ventricular ejection fraction <45% on echocardiography screening
•3. Severe aortic stenosis on echocardiography screening
•4. Already had gout or currently on allopurinol
•5. Severe hepatic disease
•6. Renal disease; CKD class 3B or worse
•7. On azathioprine, 6 mercaptopurine, or theophylline
•8. Malignancy (receiving active treatment) or other life threatening diseases
•9. Pregnant or lactating women
•10. Any contraindication to MRI (claustrophobia, metal implants, penetrative eye injury or exposure to metal fragments in eye requiring medical attention)
•11. Patients who have participated in any other clinical trial of an investigational medicinal product within the previous 30 days will be excluded
•12. Patients who are unable to give informed consent
•13. Any other considered by a study physician to be inappropriate for inclusion

发起方

The University of Dundee and NHS Tayside (UK)